These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 27578767)

  • 21. Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities.
    Stebelska K
    Ther Drug Monit; 2013 Aug; 35(4):420-42. PubMed ID: 23851905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
    Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
    Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.
    Johnson MW; Sewell RA; Griffiths RR
    Drug Alcohol Depend; 2012 Jun; 123(1-3):132-40. PubMed ID: 22129843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacology of psilocybin.
    Passie T; Seifert J; Schneider U; Emrich HM
    Addict Biol; 2002 Oct; 7(4):357-64. PubMed ID: 14578010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.
    Kopra EI; Ferris JA; Winstock AR; Young AH; Rucker JJ
    J Psychopharmacol; 2022 Aug; 36(8):965-973. PubMed ID: 35388724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
    Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR
    Psychopharmacology (Berl); 2018 Feb; 235(2):521-534. PubMed ID: 29116367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans.
    Gouzoulis-Mayfrank E; Thelen B; Maier S; Heekeren K; Kovar KA; Sass H; Spitzer M
    Neuropsychobiology; 2002; 45(4):205-12. PubMed ID: 12097810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-response relationships of psilocybin-induced subjective experiences in humans.
    Hirschfeld T; Schmidt TT
    J Psychopharmacol; 2021 Apr; 35(4):384-397. PubMed ID: 33663259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach].
    Jastrzebski M; Bala A
    Psychiatr Pol; 2013; 47(6):1157-67. PubMed ID: 25007546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magic Mushrooms - an exploratory look at how mental health professionals feel and think about Psilocybin.
    Meyer TD; Meir P; Lex C; Soares JC
    Psychiatry Res; 2022 Oct; 316():114727. PubMed ID: 35878481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.
    Kometer M; Schmidt A; Bachmann R; Studerus E; Seifritz E; Vollenweider FX
    Biol Psychiatry; 2012 Dec; 72(11):898-906. PubMed ID: 22578254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
    Bogenschutz MP; Forcehimes AA; Pommy JA; Wilcox CE; Barbosa PC; Strassman RJ
    J Psychopharmacol; 2015 Mar; 29(3):289-99. PubMed ID: 25586396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students.
    Hallock RM; Dean A; Knecht ZA; Spencer J; Taverna EC
    Drug Alcohol Depend; 2013 Jun; 130(1-3):245-8. PubMed ID: 23265089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.
    Barrett FS; Carbonaro TM; Hurwitz E; Johnson MW; Griffiths RR
    Psychopharmacology (Berl); 2018 Oct; 235(10):2915-2927. PubMed ID: 30062577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study.
    Cavanna F; Muller S; de la Fuente LA; Zamberlan F; Palmucci M; Janeckova L; Kuchar M; Pallavicini C; Tagliazucchi E
    Transl Psychiatry; 2022 Aug; 12(1):307. PubMed ID: 35918311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG.
    Gouzoulis-Mayfrank E; Schreckenberger M; Sabri O; Arning C; Thelen B; Spitzer M; Kovar KA; Hermle L; Büll U; Sass H
    Neuropsychopharmacology; 1999 Jun; 20(6):565-81. PubMed ID: 10327426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
    Griffiths RR; Johnson MW; Richards WA; Richards BD; Jesse R; MacLean KA; Barrett FS; Cosimano MP; Klinedinst MA
    J Psychopharmacol; 2018 Jan; 32(1):49-69. PubMed ID: 29020861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.
    Carter OL; Hasler F; Pettigrew JD; Wallis GM; Liu GB; Vollenweider FX
    Psychopharmacology (Berl); 2007 Dec; 195(3):415-24. PubMed ID: 17874073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of psilocybin on time perception and temporal control of behaviour in humans.
    Wittmann M; Carter O; Hasler F; Cahn BR; Grimberg U; Spring P; Hell D; Flohr H; Vollenweider FX
    J Psychopharmacol; 2007 Jan; 21(1):50-64. PubMed ID: 16714323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.